Takeda San Francisco and Pieris Sign Anticalin® Therapeutic CollaborationMay 24th, 2021
FiledMay 24th, 2021Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts around a predetermined Takeda target. The collaboration includes an option for expansion following delivery of a successful candidate to Takeda, which would lead subsequent development and commercial efforts. Further deal terms and financial details were not disclosed.